Replies to post #189 on Equity Field Notes from temporal sources

[DanWebzster]

ORGS has 2 divisions: 1) CDMO is a NASDAQ listed contract mfr/developer of cell based therapies 2) R & D program focused on converting liver cells into insulin producing cells

CDMO is growing at a rate corresponding to the Cell Therapies growth rates. CDMO grew 58% in 2017.

CDMO competes with WXXWY & LZAGY

CRSP is a significant client of CDMO, along with Servier & Zelluna.

ORGS intends to file an IND for Autologous Insulin Cell Production technology this year.

Potential catalysts include:

* Sell-side coverage. ORGS uplisted from OTC and presently has minimal institutional support
* Positive news associated with a major client. CRSP can be very news driven
* Entering into a agreement with a new mfrng/development client

[DanWebzster]

VKTX (update)

MDGL is now valued at 6x VKTX. If the H2 Ph2 NAFELD read out goes well VKTX should undergo another upward re-valuation.

In addition, VK5211 demonstrated promising signs of efficacy in a mid-stage trial in patients who recently suffered a hip fracture.

VKTX is seeking a partnership for VKTX

VKTX raised gross proceeds of $67.5mn in 6/18.